Compare ADNT & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ADNT | FTRE |
|---|---|---|
| Founded | 2016 | 1996 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.5B |
| IPO Year | 2016 | 2023 |
| Metric | ADNT | FTRE |
|---|---|---|
| Price | $24.86 | $11.00 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 10 | 10 |
| Target Price | ★ $24.85 | $15.50 |
| AVG Volume (30 Days) | 1.0M | ★ 1.7M |
| Earning Date | 05-05-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $17,439,000,000.00 | $2,696,400,000.00 |
| Revenue This Year | $2.76 | $3.21 |
| Revenue Next Year | $2.24 | $0.25 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 7.56 | N/A |
| 52 Week Low | $10.04 | $3.97 |
| 52 Week High | $27.32 | $18.67 |
| Indicator | ADNT | FTRE |
|---|---|---|
| Relative Strength Index (RSI) | 54.30 | 32.25 |
| Support Level | $25.53 | $9.42 |
| Resistance Level | $27.32 | $11.03 |
| Average True Range (ATR) | 1.15 | 1.31 |
| MACD | -0.09 | -0.44 |
| Stochastic Oscillator | 57.66 | 19.87 |
Adient began trading Oct. 31, 2016, when Johnson Controls spun off its automotive experience segment. Adient is a leading seating supplier to the industry with about a midteens share of the global market including unconsolidated joint venture business. Its share in China is around 20%, down from about 45%, following the sale of its main joint venture there at the end of fiscal 2021. Unconsolidated revenue from joint ventures was about $3.5 billion in fiscal 2025 and consolidated China revenue was $1.3 billion. The company is headquartered in Ireland but has corporate offices in the Detroit area. Fiscal 2025 (Sept. 30 year-end) consolidated revenue, which excludes joint venture sales, was $14.5 billion.
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.